Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Total Liabilities (2022 - 2025)

TriSalus Life Sciences' Total Liabilities history spans 4 years, with the latest figure at $69.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 38.76% year-over-year to $69.2 million; the TTM value through Dec 2025 reached $69.2 million, up 38.76%, while the annual FY2025 figure was $69.2 million, 38.76% up from the prior year.
  • Total Liabilities reached $69.2 million in Q4 2025 per TLSIW's latest filing, up from $63.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $69.2 million in Q4 2025 to a low of $12.0 million in Q2 2022.
  • Average Total Liabilities over 4 years is $40.1 million, with a median of $48.9 million recorded in 2024.
  • The largest YoY upside for Total Liabilities was 271.65% in 2024 against a maximum downside of 3.48% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $34.3 million in 2022, then surged by 50.54% to $51.7 million in 2023, then decreased by 3.48% to $49.9 million in 2024, then skyrocketed by 38.76% to $69.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Total Liabilities are $69.2 million (Q4 2025), $63.2 million (Q3 2025), and $60.7 million (Q2 2025).